Single high-dose radiation for prostate cancer returning after surgery
Studies one precise radiation dose for men whose prostate cancer returned.
Key facts
- Who runs it
- University of Milano Bicocca
- Where
- Monza, ItalySee the site
- Trial code
- Registry title
- Salvage Ultrahypofractionated Postoperative External Radiotherapy For Biochemical Recurrence
- Status
- Recruiting
- People taking part
- 50 people, planned
- Started
- 2 May 2025
- Expected to end
- May 2033
- Type of study
- Observational
- Treatments tested
- SDRT
- Record updated
- 2 February 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men whose PSA has become detectable after prostate cancer surgery. They will get one high-dose radiation treatment to the area where the prostate was.
- Age
- 18 to 90 years
- Sex
- Men only
- Disease stage
- Prostate cancer (adenocarcinoma) treated with radical prostatectomy. PSA of 0.1 to under 2.0 ng/mL, either always detectable after surgery or rising again. No sign of spread to lymph nodes (N1) or elsewhere (M1) on a PSMA PET-CT done within 90 days before registration.
- Earlier treatment
- Must have had radical prostatectomy, with no time limit. Hormone therapy (ADT) is allowed at the doctor's discretion. No earlier radiation to the prostate gland or pelvis, and no brachytherapy.
- Biomarker or test result
- PSA of 0.1 to under 2.0 ng/mL after prostatectomy. A negative pelvic MRI is needed if the PSMA PET-CT is unclear about local relapse.
Main reasons for not taking part
- Spread to lymph nodes (N1) or elsewhere (M1)
- Visible local relapse on pelvic MRI
- Earlier radiation to the prostate or pelvis, or brachytherapy
- History of inflammatory colitis or other active severe illnesses
- Taking immunosuppressant medicines
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Subjects of male sex ≥ 18 years of age
- Subjects have freely signed the pertinent informed consent before the beginning of the study; Adenocarcinoma of the prostate treated with radical prostatectomy (any type of radical prostatectomy is permitted including retropubic, perineal, laparoscopic or robotically assisted; there is no time limit for the date of radical prostatectomy); Detectable post-prostatectomy PSA of ≥ 0.1 - < 2.0 ng/mL either (1) persistently detectable post-operatively or (2) developing biochemical recurrence after prostatectomy (initially undetectable); No evidence of N1 and/or M1 disease assessed by PSMA PET-CT within 90 days prior to registration; Negative Magnetic Resonance Imaging (MRI) of the pelvis in case of equivocal evidence of local relapse on PSMA PET-CT; Androgen deprivation therapy (ADT) allowed as per physician's discretion; ECOG performance status of 0-1; Ability to complete the questionnaires
Who cannot take part
- Prior radiation of any kind to the prostate gland or pelvis
- Prior brachytherapy
- Patients who are on immunosuppressant medication
- History of inflammatory colitis or other active severe comorbidities
- N1 and or M1 patients
- Macroscopic local relapse at pelvic MRI
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 90 years old?
Where in Italy
- Radiation Oncology, Fondazione IRCCS San Gerardo dei Tintori (University of Milan Bicocca)Monza, ItalyContact: Stefano Arcangeli, MDTaking people
About the trial
What the trial wants to find out
Recently, the Radiation Oncology Department at Fondazione IRCCS San Gerardo dei Tintori has been renovated and has been equipped with cutting edge technologies to treat prostate cancer. Specifically, the now available technology can track organ motion in real time, thus allowing improved precision in radiation delivery, with increased protection of the surrounding organs at risk. These facilities have already enabled the kickoff of two prospective observational trials, the ABRUPT and the POPART, which are currently ongoing in the treatment of intact prostate and the biochemical recurrence, respectively. Taken together, these observations provide the basis for the prospective clinical study herein proposed. Patients enrolled in the study will undergo salvage single stereotactic RT to the prostate bed by means of image guided volumetric intensity-modulated arc technique (IGRT-VMAT) and state-of-the-art treatment-planning and quality assurance procedures, with emphasis on normal tissue sparing and and pinpoint delivery accuracy via the use of devices that ensure stability and beam location reproducibility
The group in the trial
- 1 fx SDRT
Treatment: SDRT
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Salvage Ultrahypofractionated Postoperative External Radiotherapy For Biochemical Recurrence
- Plain-language title
- Single high-dose radiation for prostate cancer returning after surgeryGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06941363, who can take part
- Record updated
- 2 February 2026